268 reports of this reaction
2.8% of all EDOXABAN TOSYLATE reports
#3 most reported adverse reaction
RENAL IMPAIRMENT is the #3 most commonly reported adverse reaction for EDOXABAN TOSYLATE, manufactured by Daiichi Sankyo Inc.. There are 268 FDA adverse event reports linking EDOXABAN TOSYLATE to RENAL IMPAIRMENT. This represents approximately 2.8% of all 9,635 adverse event reports for this drug.
Patients taking EDOXABAN TOSYLATE who experience renal impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL IMPAIRMENT is a less commonly reported adverse event for EDOXABAN TOSYLATE, but still significant enough to appear in the safety profile.
In addition to renal impairment, the following adverse reactions have been reported for EDOXABAN TOSYLATE:
The following drugs have also been linked to renal impairment in FDA adverse event reports:
RENAL IMPAIRMENT has been reported as an adverse event in 268 FDA reports for EDOXABAN TOSYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL IMPAIRMENT accounts for approximately 2.8% of all adverse event reports for EDOXABAN TOSYLATE, making it one of the most commonly reported side effect.
If you experience renal impairment while taking EDOXABAN TOSYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.